Mexichem Acquires License for DuPont’s Medical Propellant
Mexichem announced that it acquired the distribution and sale license for HFC-227ea/P from Du Pont.
Mexichem announced on Dec. 31, 2014 that it acquired the distribution and sale license for pharmaceutical grade HFC-227ea/P, a medical propellant, from DuPont de Nemours and Company. The product, which is used to safely deliver drugs in aerosol form, will be added to Mexichem’s existing Zephex brand of medical propellants, which make up around 75% of the inhalers produced worldwide, according to the press release.
“Since 1995 Zephex products have filled around 3.5 billion inhalers, helping to improve the lives of over 100 million people every year. This acquisition highlights our continued commitment to leading the market and will allow us to further support a valuable part of our customer’s product portfolios,” said Simon Gardner, general manager of Mexichem Fluor Medical Products, in a press release.
Source: Mexichem
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
